Literature DB >> 10405003

Radiobiological effects of docetaxel (Taxotere): a potential radiation sensitizer.

M Creane1, C B Seymour, S Colucci, C Mothersill.   

Abstract

PURPOSE: To investigate the ability of docetaxel (Taxotere) to radiosensitize human cell lines of differing malignant status, intrinsic radiosensitivity and p53 status.
MATERIALS AND METHODS: Cell survival following treatment with drug and/or radiation was determined by colony-forming assay on two malignant human colon cell lines of widely different radiosensitivity (HT29 and SW48). An immortal human keratinocyte line (HaCaT), which does not form tumours in nude mice, was used to assess the effect on non-malignant human epithelium.
RESULTS: The experiments indicate that docetaxel had the greatest cytotoxic and radiosensitizing effect on the SW48 (p53wt) cell line. The degree of radiosensitization was not improved by increasing the drug concentration, although the overall cytotoxicity was increased with increasing concentrations of the two agents. Both p53mut lines were less sensitive to the drug, irrespective of their malignant potential.
CONCLUSION: The results support a role for Taxotere as a weak radiosensitizer of the three cell lines tested. The p53 status and intrinsic radiosensitivity may be relevant to the mechanism.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10405003     DOI: 10.1080/095530099140078

Source DB:  PubMed          Journal:  Int J Radiat Biol        ISSN: 0955-3002            Impact factor:   2.694


  17 in total

Review 1.  Docetaxel: a review of its use in non-small cell lung cancer.

Authors:  A M Comer; K L Goa
Journal:  Drugs Aging       Date:  2000-07       Impact factor: 3.923

2.  Long-term outcome of a phase II study of docetaxel-based multimodality chemoradiotherapy for locally advanced carcinoma of the esophagus or gastroesophageal junction.

Authors:  Nicholas W Choong; Ann M Mauer; Daniel C Haraf; Mark K Ferguson; Alan B Sandler; Kenneth A Kesler; Paul A S Fishkin; Rafat H Ansari; James Wade; Stuart A Krauss; David F Sciortino; Mitchell C Posner; Masha Kocherginsky; Philip C Hoffman; Livia Szeto; Everett E Vokes
Journal:  Med Oncol       Date:  2010-08-21       Impact factor: 3.064

3.  Radiation-sensitizing effect of low-concentration docetaxel on human esophageal squamous cell carcinoma cell lines.

Authors:  Satoshi Tabuchi; Soji Ozawa; Kazuo Koyanagi; Naoyuki Shigematsu; Atsushi Kubo; Masakazu Ueda; Yuko Kitagawa; Masaki Kitajima
Journal:  Exp Ther Med       Date:  2011-05-10       Impact factor: 2.447

4.  Docetaxel shows radiosensitization in human hepatocellular carcinoma cells.

Authors:  Chang-Xin Geng; Zhao-Chong Zeng; Ji-Yao Wang; Shi-Ying Xuan; Chong-Mao Lin
Journal:  World J Gastroenterol       Date:  2005-05-21       Impact factor: 5.742

5.  A study of Docetaxel-induced effects in MCF-7 cells by means of Raman microspectroscopy.

Authors:  Katharina Hartmann; Melanie Becker-Putsche; Thomas Bocklitz; Katharina Pachmann; Axel Niendorf; Petra Rösch; Jürgen Popp
Journal:  Anal Bioanal Chem       Date:  2012-03-08       Impact factor: 4.142

6.  Docetaxel-based induction therapy prior to radiotherapy with or without docetaxel for non-small-cell lung cancer.

Authors:  G V Scagliotti; A Szczesna; R Ramlau; F Cardenal; K Mattson; N Van Zandwijk; A Price; B Lebeau; J Debus; C Manegold
Journal:  Br J Cancer       Date:  2006-05-22       Impact factor: 7.640

7.  The role of apoptotic cell death in the radiosensitising effect of gemcitabine.

Authors:  B Pauwels; J B Vermorken; A Wouters; J Ides; S Van Laere; H A J Lambrechts; G G O Pattyn; K Vermeulen; P Meijnders; F Lardon
Journal:  Br J Cancer       Date:  2009-08-18       Impact factor: 7.640

8.  Pharmacokinetic analysis of two different docetaxel dose levels in patients with non-small cell lung cancer treated with docetaxel as monotherapy or with concurrent radiotherapy.

Authors:  Paal F R Brunsvig; Anders Andersen; Steinar Aamdal; Vessela Kristensen; Harald Olsen
Journal:  BMC Cancer       Date:  2007-10-23       Impact factor: 4.430

9.  Preoperative concurrent chemoradiotherapy with cisplatin and docetaxel in patients with locally advanced non-small-cell lung cancer.

Authors:  H Katayama; H Ueoka; K Kiura; M Tabata; T Kozuki; M Tanimoto; T Fujiwara; N Tanaka; H Date; M Aoe; N Shimizu; M Takemoto; Y Hiraki
Journal:  Br J Cancer       Date:  2004-03-08       Impact factor: 7.640

Review 10.  Docetaxel induction therapy in locally advanced squamous cell carcinoma of the head and neck.

Authors:  M R Posner; J L Lefebvre
Journal:  Br J Cancer       Date:  2003-01-13       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.